Plain-English translation of NCT07028489 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is building a database of patients with advanced lung cancer that has a specific genetic mutation (EGFR mutation) who are starting treatment with osimertinib, either alone or combined with chemotherapy. Researchers will collect standardized health information at the start of treatment, during treatment, and when treatment stops. The goal is to better understand how well this medication works and how it affects patients over time.
Doctors need real-world information about how patients respond to this treatment in everyday practice, not just in controlled research settings. This data will help improve future care and treatment decisions for people with this type of lung cancer.
You likely qualify if…
You likely don't qualify if…
You would enroll before or right as you start your cancer treatment. Researchers will collect information about your health at the beginning, regularly while you're being treated, and after your treatment ends. If you enroll before starting treatment, you'll also have imaging scans done on a set schedule. The study involves sharing your medical records and undergoing standardized data collection visits, but you continue your regular cancer care with your own doctor.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States